-
Mashup Score: 0Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma - 8 month(s) ago
The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
Source: blog-ecog-acrin.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma (NDMM) [Feb 25, 2021] https://t.co/HgKq2Kdtxq PI = @myelomaMD https://t.co/VNFtlcWGml #NCT04566328 #mmsm n=1450 @eaonc